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Abstract | The term chronic traumatic encephalopathy (CTE) has recently entered public 
consciousness via media reports and even a Hollywood movie. However, in contrast to general 
impressions, the incidence of CTE is unknown, the clinical diagnostic criteria have not been 
agreed and the current neuropathological characterization of CTE is acknowledged as 
preliminary. Additionally, few studies have compared the pathologies of CTE with those of other 
neurodegenerative disorders or of age-matched controls. Consequently, disagreement 
continues about the neuropathological aspects that make CTE unique. Furthermore, CTE is 
widely considered a consequence of exposure to repeated head blows but emerging evidence 
suggests that a single moderate or severe traumatic brain injury (TBI) can also induce 
progressive neuropathological changes. These unresolved aspects of CTE underlie disparate 
claims about its clinical and pathological features, leading to confusion among the public and 




In little more than a decade, the term chronic traumatic encephalopathy (CTE) has 
emerged into public consciousness via intense media coverage. The issue has even 
spawned numerous documentaries and is the subject of a Hollywood movie in which a 
neuropathologist is the protagonist1. This media attention has helped increase 
awareness of  an important public health concern, but has often included inaccurate or 
confusing descriptions of the fundamental aspects of CTE, causing undue alarm. For 
example, news stories have implied a link between suicide and brain pathologies in 
former athletes, but no evidence supports this association. Other reports suggest that 
degenerative brain disease is almost inevitable for participants in some sports2,3, but 
the actual incidence of CTE remains unknown4. Furthermore, despite the widely held 
impression that the neuropathology of CTE has been fully characterized, current 
consensus neuropathological criteria are acknowledged as only preliminary, in part 
because these criteria are based on a limited number of selected cases5. As a 
consequence, many disparate claims about the clinical and pathological features of 
CTE continue to confuse not only the general public, but also healthcare professionals. 
Nonetheless, behind the hyperbole, a long history of CTE (Fig. 1) points the way 
forward to a better understanding of the association between traumatic brain injury 
(TBI) and late neurodegeneration.  
Here we examine the long history of CTE from its first description as a neuropsychiatric 
entity in boxers through to the current understanding of its neuropathological 
characteristics from a wide range of TBI exposures.  We also address areas where the 
public perception of CTE and the scientific literature do not align, and the associated 
controversies.   
 
 
History versus headlines  
Although the term CTE has only recently entered the public vocabulary, an association 
between repeated head blows and early dementia has been recognized for over 90 
years. In 1928 Martland first described the chronic neuropsychiatric sequelae of boxing 
as the “punch drunk” syndrome6, which was subsequently referred to as dementia 
pugilistica. Multiple subsequent reports elaborated on these early observations and 
generated a somewhat consistent and characteristic clinical picture7-10, which included 
psychiatric symptoms, emotional lability, personality changes, memory impairment and 
dementia, pyramidal and extrapyramidal dysfunction, and cerebellar impairment. Some 
four decades later, in 1969, a comprehensive study of 224 randomly selected, living 
professional boxers demonstrated that 17% exhibited a “relatively stereotyped clinical 
pattern” consistent with a degree of neurological impairment11.  
Despite this long experience with dementia pugilistica, it has now been 
subsumed into CTE, a clinical entity that is more encompassing but is also more 
vague, a problem that has resulted in misunderstanding and controversy. Particular 
confusion has arisen around symptoms such as suicidality, aggression and 
disinhibition, which were not characterized in dementia pugilistica, but have been 
described  in contemporary series of non-boxer athletes diagnosed with CTE at 
autopsy3,12. This issue could be exacerbated by the fact that, at present, CTE is 
defined by neuropathology rather than formal clinicopathological correlation. In 
addition, the general perception that athletes in other sports are also at increased risk 
of suicide and dementia associated with repetitive mild TBI-induced neuropathology 
seems to be based on multiple high-profile media reports rather than on evidence from 
adequately powered and unbiased scientific studies. Indeed, in a study looking at 
retired American National Football League players between 1979 and 2013, the 
suicide rate was actually lower than among the general public13. Nevertheless, in more 
recent studies, the suicide rate among individuals with autopsy identified CTE is 
reported as higher than anticipated3, which, if confirmed, might suggest a recent 
change in suicidality among former NFL athletes, and area that clearly will require 
careful Prospective studies of athletes involved in contact sports other than boxing 
currently underway may help resolve the incidence and characteristics of the 
neuropsychiatric profile of CTE, including suicidality, and determine if these differ from 
those observed long ago in boxers.    
 
Not new, just newly publicized  
Despite several decades of suspicion that boxing could lead to progressive 
neurodegeneration, the neuropathology of a boxer with dementia was not described 
until the report of Brandenburg and Hallervorden in195414. Two decades later, in a 
landmark autopsy study of former professional and amateur boxers, Corsellis and 
colleagues detailed stereotypical neuropathological findings associated with dementia 
pugilistica15 that continue to be elaborated today. However, these observations raised 
little interest from the public or the research community, perhaps owing to the 
misperception that boxing is unique with regards to head impacts and repetitive mild 
TBI. 
Despite media claims and the narrative of the movie Concussion1, CTE is not a 
new disease entity; the recognition that the condition can occur in contact sports and 
contexts other than boxing is what is new. In particular, neuropathological findings 
similar to those previously described in boxers have been reported in players of 
American football, ice hockey, soccer and rugby12,16-21, and in military personnel22,23. In 
addition, identification of similar pathology in individuals who have experienced a have 
drawn attention to the possibility that CTE-like pathology can be associated with the full 
spectrum of TBI severity.  
 
 
Tangled impressions about tau 
Features of tau pathology that might characterize CTE have been identified, but 
disagreement exists about the validity of this histopathological characterization. 
Current evidence suggests that the distribution of tau neurofibrillary tangles in TBI-
associated neurodegeneration is distinct from that in other neurodegenerative disease. 
In multiple accounts of CTE in the past three decades14,18-26, cortical pathology has 
been described as a patchy distribution of hyperphosphorylated tau deposits in 
neurons and glia, typically in perivascular locations and with a preferential distribution 
towards the depths of cortical sulci5. These observations form the core of the current 
consensus criteria for the neuropathological diagnosis of CTE5, with some people 
already considering this anatomical distribution of tau pathology to be pathognomonic. 
However, remarkably few cases have been described in the literature and these 
consensus criteria are acknowledged as being preliminary, in part because they are 
based on review of autopsy derived material from just ten selected CTE cases.  
Whether the distribution of neurofibrillary tangles is sufficient to diagnose  a 
neuropathologically distinct neurodegenerative disorder, regardless of the clinical 
syndrome or previous exposure to TBI, remains unclear. Notably, a review of tissue 
samples from the Queen Square Brain Bank (London, UK) identified the so-called 
pathognomonic tau pathology of CTE in 12% of cases examined, whether or not the 
individual had a history of neurodegenerative disease20. H o w e v e r ,  common to all 
cases where CTE pathology was present in this study was previous exposure to TBI. 
On this basis, the tau pathology that is currently considered as being characteristic of 
CTE might indicate exposure to TBI, but not necessarily neurodegenerative disease 
per se. Furthermore, the fact that a limited numbers of cases have been evaluated to 
date means that attempts to stage neurodegenerative disease on the basis of 
neurofibrillary tangle distribution must remain speculative12,27. These uncertainties are 
reinforced by disparities between pathological descriptions. For example, early studies 
of pathology in boxers identified that tau pathology was most abundant in the medial 
temporal lobe15,26, whereas subsequent studies suggest relative sparing of the medial 
temporal lobe5,12,18,19. 
 
More than a tauopathy  
In contemporary reports, the designation of CTE has often been based on the 
presence of tau pathology alone28. Neurofibrillary tangles are undoubtedly one of the 
most consistently described pathologies in patients with CTE5,25, but historic accounts 
and other contemporary case series make clear that post-TBI neurodegeneration is a 
multi-faceted pathology (Fig. 2); the additional pathologies that have been described 
are discussed below. In future, the constellation of neuropathological changes that are 
linked with a history of exposure to TBI will continue to expand, as has been the case for 
many other neurodegenerative diseases. Nonetheless, on the basis of only the current 




Amyloid-β (Aβ) pathology has frequently been identified alongside tau pathologies in 
post-TBI neurodegeneration In a re-examination of Corsellis’ original series with further 
cases added, 19 of 20 former boxers were found to have diffuse Aβ plaques29. Case 
series of non-boxer athletes have also demonstrated a high prevalence of Aβ 
pathology, which increases with higher age at death3,25,30. As such, whether Aβ 
pathology in CTE is directly linked to a history of exposure to TBI or is simply age-
related remains to be elucidated. Notably, individuals with Aβ pathology also had 
clinical symptoms of cognitive impairment. Given that a limited number of cases have 
been examined and age-matched controls have not been used, further studies are 
undoubtedly required to determine the role of Aβ pathology in CTE before concluding 
that this pathology is incidental.  
 
TDP43 
Some evidence suggests that the 43 kDa transactive response (TAR) DNA-binding 
protein (TDP43) is involved in post-TBI neurodegeneration. In some conditions, TDP43 
translocates from nucleus to cytoplasm, where it can become polyubiquitinated and 
hyperphosphorylated and forms pathological inclusion bodies31. TDP43 is increasingly 
recognized as a major disease-associated protein in several neurodegenerative 
conditions, including frontotemporal lobar dementia and amyotrophic lateral sclerosis 
(ALS)33,34, and as a minor component in various other conditions, such as Alzheimer 
disease (AD) and Parkinson disease31,34,35. Autopsy studies of former boxers, 
American football and hockey players have identified neuronal cytoplasmic TDP43 
inclusions and distinctive ‘grain-like’ profiles in the surrounding neuropil in multiple 
regions7,37,38. In a small number of patients with ALS, autopsy studies have identified 
the tau pathology of CTE alongside TDP43 pathology7. However, these few 
observations are not enough to conclude that the observed pathology represents an 
ALS-like variant of CTE (a condition that has been referred to as CTE plus motor 
neuron disease) or simply ALS with coincident CTE-like tau pathology. 
 
Atrophy 
Acute and chronic axon degeneration after a single, severe TBI has been well 
described, but white matter changes after repetitive mild TBI have also been observed 
and described as evidence of gliosis, foci of white matter degeneration or 
rarefaction15,38,39, and patchy loss of myelin staining15,17,38,40. Similarly, evidence of 
neuroinflammation has been observed, albeit in few case series15,17,39,41,42. In addition, 
brain atrophy is frequently observed in boxers with symptoms of CTE, mainly in the 
frontal and temporal lobes and the cerebellum8,40,43,44. In most descriptions of CTE in 
boxers8,15,25,38,39,41 and in many in non-boxer athletes12,21,25, pathologies observed 
include abnormalities of the septum pellucidum, including cavum septum pellucidum, 
which are often associated with ventricular dilation. 
 
Neurodegeneration after a single TBI  
Substantial epidemiological evidence demonstrates that exposure to just a single 
moderate to severe TBI is associated with an increased risk of late 
neurodegeneration4,6,46-52. In the reports to date, which have typically been based on 
retrospective studies, the dementia that follows a single TBI is often classified as AD-
like, although none of these studies have included confirmation of the neuropathology at 
autopsy. Consequently, the presumption that AD follows a single moderate to severe 
TBI is, at best, speculative. Nonetheless, the idea that repetitive mild TBI leads to CTE 
but that a single moderate to severe TBI leads to AD is often put forward28. However, a 
series of studies show that almost all of the neuropathological changes described in 
boxers and non-boxer athletes as a result of repetitive mild TBI can also be observed in 
people years after they have experienced a single moderate to severe TBI24,51,25,52.  
 
Can CTE follow a single TBI?  
Analysis of non-selected brain tissue samples from individuals in the Glasgow TBI 
Archive (UK) who survived for ≥1 year after a single moderate to severe TBI revealed a 
greater density and wider distribution of both NFTs and Aβ plaques in ~30% of patients 
than observed in age-matched controls who had not experienced a TBI24. However, 
these proteinopathies followed different temporal courses. Pathological examination 
within months of a single moderate to severe TBI did not reveal the presence of any 
neurofibrillary tangles56, yet abundant neurofibrillary tangles were observed beyond 
1 year55, suggesting that the processes that drive formation of neurofibrillary tangles 
after TBI might progress over months to years. By contrast, Aβ pathology after a single 
moderate to severe TBI seems to develop much faster. Notably, in a large animal 
model of TBI54 and in a study of human brain tissue55, a unique mechanism of Aβ 
production after TBI has been linked to progressive axonal pathology. Specifically, 
massive accumulation of amyloid precursor protein, presenilin-1 and β-secretase 1 in 
damaged axons shortly after injury triggers formation of Aβ within the axon membrane 
compartment56. This extensive genesis and release of Aβ from lysing axons might 
account for the Aβ plaques that are seen in ~30% patients who die as a result of a 
moderate or severe TBI57,58 and in brain tissue that is surgically excised from 
individuals who have survived a moderate to severe TBI59.  
Surprisingly, these Aβ plaques can be observed within hours of injury, and are 
associated with polymorphisms in the genes that encode apolipoprotein E60 and 
neprilysin61. By contrast, few Aβ plaques are found in the brains of individuals who 
survive a single moderate to severe TBI several months after the injury, but beyond 
1 year, plaques reappear at a higher density than in age-matched controls24. In these 
individuals, fibrillar Aβ plaques were observed in addition to diffuse plaques. Notably, 
chronic neuroinflammation  has been observed to last for decades after a single 
moderate to severe TBI in association with ongoing white matter loss and axonal 
degeneration51, which may play a role in the chronic formation of Aβ plaques. 
The TDP43 proteinopathy observed in some people who have experienced 
repetitive mild TBI does not seem to develop in people who survive a single moderate to 
severe TBI62 (Fig. 2). This observation raises the intriguing possibility that some 
pathological processes are shared across the spectrum of TBI severity, whereas 
others differ.   
 
[H1] Conclusions and the evolution of CTE   
Ninety years since Martland’s original description of the ‘punch drunk’ syndrome6, 
numerous key questions about CTE remain unanswered. By all accounts to date, the 
clinicopathological heterogeneity of CTE rivals that of AD and other neurodegenerative 
disorders. To allow meaningful clinical research into CTE, there is a pressing need to 
achieve consensus about the clinical and neuropathological operational diagnostic 
criteria for CTE. In parallel, the question of whether the pathologies that have been 
described after a single moderate to severe TBI are the same as the pathologies that 
develop after repetitive mild TBI needs to be answered. More studies are needed to 
resolve this question, but on the basis of the current literature, the pathologies 
associated with survival of TBI seem to be as heterogeneous as the forms of TBI 
themselves. Considering the many shared pathological features that have been 
described, the changes could indicate a TBI dose effect, whereby a threshold that 
triggers neurodegenerative cascades can be reached as a result of one severe TBI or 
the cumulative effects of repeated multiple mild TBI.  Notably, it remains to be 
determined if exposure to repeated head impacts in the absence of diagnosed TBI, as 
so-called “sub-concussive blows,” can also trigger neurodegeneration. 
While we await full and rigorous characterization of CTE, the current evidence 
does not support the widely accepted premise that CTE is exclusively a tauopathy that 
occurs only in people who have been exposed to repetitive mild TBI. Neither does the 
evidence support the idea that neurodegeneration after exposure to a single moderate 
to severe TBI is inevitably AD. Unquestionably, CTE encompasses a broader range of 
neuropathologies and outcomes after TBI of varying severity, and time will tell whether 
the condition is a distinct disease entity or is linked with other neurodegenerative 
processes such as AD. However, as the term CTE has become embedded in the public 
consciousness and is continually fortified by the media, we are obliged to continue with 
the term. Meanwhile, the words of Corsellis from his original account of boxers over four 
decades ago are as relevant now as they were then: “most of the trenchant views that 
are expressed about the vulnerability, as well as the immunity, of the brain in [sport] 
are still based more on supposition than on fact”15. 
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Figure 1 | Timeline of developments and the cumulative number of cases  of dementia 
pugilistica and chronic traumatic encephalopathy. The association between exposure to 
brain injury in boxing and the risk of neurodegenerative disease was first reported by 
Martland in 19286.Occasional isolated cases were subsequently added to the literature 
until the landmark publication by Corsellis et al. in 1973Continued reports of isolated 
cases and small case series added to the cumulative experience of CTE and since the 
first description of the pathology in a former National Football League player in 2005, a 
marked increase in case identification and reporting has been seen, in part informed by 
publication of the preliminary criteria for the neuropathology diagnosis of CTE. 
Nevertheless, the cumulative number of unique CTE cases reported is currently just 
over 300.  
 
Figure 2 | Neuropathologies  identified as being associated with 
neurodegeneration after traumatic brain injury. Post-mortem neuropathology studies 
have identified that brain atrophy associated with abnormalities in tau, amyloid-β and 
and persistent neuroinflammation in the brains of people who were exposed to repetitive 
mild traumatic brain injury (TBI) or a single moderate or severe TBI. In addition, TDP43-
associated axonal degeneration has been identified in association with repetitive mild 
TBI. Although no studies have directly compared the pathology of repetitive mild TBI to 
that of single moderate or severe TBI in humans, reports indicate similarity of many of 
these pathologies.  
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